lomitapide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
microsomal triglyceride transfer protein (MTP) inhibitors 4721 182431-12-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • lomitapide
  • juxtapid
  • BMS-201038
  • lomitapide mesylate
  • lojuxta
  • lomitapide mesilate
  • BMS201038
  • BMS 201038
an anticholesteremic agent and microsomal triglycide transfer protein inhibitor
  • Molecular weight: 693.73
  • Formula: C39H37F6N3O2
  • CLOGP: 6.69
  • LIPINSKI: 2
  • HAC: 5
  • HDO: 2
  • TPSA: 61.44
  • ALOGS: -6.89
  • ROTB: 12
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
40 mg O

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 16.30 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 8.70 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.00 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 39.70 hours Lombardo F, Berellini G, Obach RS
BA (Bioavailability) 0.07 % Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 4.661 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 4.159 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 9.462 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 12.134 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 0.470 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 1.990 % High 1
herg hERG pIC50 5.951 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 8.072 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 111.173 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 0.660 % High 1
kinase-safety-class ACVR2B,AKT2,AXL,BRAF,CAMK2B,CAMK2D,CDK5,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAPK10,MET,NTRK2,PDK1,PDK2,PDK4,PRKDC 19
kinase-selectivity-class AXL 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 4.808 High 1
mh-clint Mouse hepatocyte intrinsic clearance 25.351 High 1
mppb Mouse plasma protein binding (% unbound) 0.620 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 22.080 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 1
pppb Pig plasma protein binding (% unbound) 1.400 % High 1
rh-clint Rat hepatocyte intrinsic clearance 31.696 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 2.640 % High 1
rppb Rat plasma protein binding (% unbound) 0.600 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 4.645 uM High 1

Approvals:

DateAgencyCompanyOrphan
Dec. 21, 2012 FDA AEGERION

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Therapy cessation 1148.56 37.91 276 3829 36085 90588257
Diarrhoea 448.67 37.91 353 3752 938837 89685505
Weight decreased 423.95 37.91 243 3862 379667 90244675
Flatulence 219.18 37.91 79 4026 41288 90583054
Low density lipoprotein increased 206.39 37.91 52 4053 8033 90616309
Diet noncompliance 160.62 37.91 26 4079 414 90623928
Nausea 160.09 37.91 221 3884 1110095 89514247
Inappropriate schedule of product administration 100.58 37.91 70 4035 149863 90474479
Abdominal pain upper 99.52 37.91 97 4008 332577 90291765
Product dose omission issue 88.96 37.91 86 4019 291601 90332741
Hepatic steatosis 73.23 37.91 35 4070 36910 90587432
Product administered to patient of inappropriate age 57.88 37.91 17 4088 4636 90619706
Abdominal distension 50.38 37.91 44 4061 130557 90493785
Blood cholesterol increased 48.20 37.91 53 4052 207959 90416383
Non-high-density lipoprotein cholesterol increased 45.86 37.91 8 4097 203 90624139
International normalised ratio increased 43.62 37.91 27 4078 47289 90577053
Alanine aminotransferase increased 41.92 37.91 38 4067 118300 90506042
Aspartate aminotransferase increased 40.33 37.91 35 4070 102902 90521440

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Therapy cessation 470.10 61.23 121 1860 20329 42599025
Weight decreased 339.72 61.23 172 1809 207776 42411578
Diarrhoea 226.76 61.23 178 1803 460671 42158683
Flatulence 128.32 61.23 47 1934 25105 42594249
Diet noncompliance 124.38 61.23 19 1962 198 42619156
Low density lipoprotein increased 119.06 61.23 31 1950 5324 42614030
Product dose omission issue 90.78 61.23 67 1914 154298 42465056
Abdominal discomfort 63.78 61.23 41 1940 75214 42544140

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Therapy cessation 1265.47 44.61 310 4618 44547 110539824
Weight decreased 536.97 44.61 303 4625 467754 110116617
Diarrhoea 532.49 44.61 420 4508 1139085 109445286
Flatulence 275.72 44.61 99 4829 52050 110532321
Low density lipoprotein increased 226.29 44.61 59 4869 10607 110573764
Nausea 195.08 44.61 255 4673 1235435 109348936
Diet noncompliance 118.85 44.61 21 4907 585 110583786
Abdominal pain upper 117.70 44.61 108 4820 349003 110235368
Product dose omission issue 101.55 44.61 96 4832 321686 110262685
Inappropriate schedule of product administration 92.92 44.61 75 4853 203562 110380809
Product administered to patient of inappropriate age 90.15 44.61 27 4901 8009 110576362
Alanine aminotransferase increased 84.49 44.61 68 4860 183705 110400666
Hepatic steatosis 72.99 44.61 38 4890 48793 110535578
Non-high-density lipoprotein cholesterol increased 72.48 44.61 13 4915 395 110583976
Aspartate aminotransferase increased 64.75 44.61 55 4873 159881 110424490
Abdominal discomfort 60.84 44.61 81 4847 393777 110190594
Abdominal distension 60.44 44.61 55 4873 175048 110409323
Blood cholesterol increased 57.90 44.61 55 4873 184730 110399641
Very low density lipoprotein increased 54.60 44.61 10 4918 342 110584029

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C10AX12 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, PLAIN
Other lipid modifying agents
FDA MoA N0000182141 Cytochrome P450 3A4 Inhibitors
FDA MoA N0000185503 P-Glycoprotein Inhibitors
FDA MoA N0000186778 Microsomal Triglyceride Transfer Protein Inhibitors
FDA EPC N0000186779 Microsomal Triglyceride Transfer Protein Inhibitor
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35821 anticholesteremic drug
CHEBI has role CHEBI:72298 MTP inhibitor

Related Drugs by ATC class:

C10AX Other lipid modifying agents 15 drugs
alipogene tiparvovecalirocumabbempedoic aciddextrothyroxineevinacumabevolocumabezetimibeinclisiranlerodalcibep-ligameglutolmipomersenpolicosanol show all 15 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Familial hypercholesterolemia - homozygous indication 238078005




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.28 acidic
pKa2 13.97 acidic
pKa3 8.71 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 10MG BASE JUXTAPID CHIESI N203858 Dec. 21, 2012 RX CAPSULE ORAL 7932268 Aug. 19, 2027 A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
EQ 20MG BASE JUXTAPID CHIESI N203858 Dec. 21, 2012 RX CAPSULE ORAL 7932268 Aug. 19, 2027 A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
EQ 2MG BASE JUXTAPID CHIESI N203858 Feb. 25, 2026 RX CAPSULE ORAL 7932268 Aug. 19, 2027 A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
EQ 30MG BASE JUXTAPID CHIESI N203858 April 23, 2015 RX CAPSULE ORAL 7932268 Aug. 19, 2027 A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
EQ 40MG BASE JUXTAPID CHIESI N203858 April 23, 2015 DISCN CAPSULE ORAL 7932268 Aug. 19, 2027 A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
EQ 5MG BASE JUXTAPID CHIESI N203858 Dec. 21, 2012 RX CAPSULE ORAL 7932268 Aug. 19, 2027 A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
EQ 60MG BASE JUXTAPID CHIESI N203858 April 23, 2015 DISCN CAPSULE ORAL 7932268 Aug. 19, 2027 A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
EQ 10MG BASE JUXTAPID CHIESI N203858 Dec. 21, 2012 RX CAPSULE ORAL 12472172 July 29, 2041 DOSING REGIMEN TO REDUCE LOW DENSITY LIPOPROTEIN CHOLESTEROL IN PEDIATRIC PATIENTS AGED 5 TO 15 YEARS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
EQ 20MG BASE JUXTAPID CHIESI N203858 Dec. 21, 2012 RX CAPSULE ORAL 12472172 July 29, 2041 DOSING REGIMEN TO REDUCE LOW DENSITY LIPOPROTEIN CHOLESTEROL IN PEDIATRIC PATIENTS AGED 5 TO 15 YEARS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
EQ 2MG BASE JUXTAPID CHIESI N203858 Feb. 25, 2026 RX CAPSULE ORAL 12472172 July 29, 2041 DOSING REGIMEN TO REDUCE LOW DENSITY LIPOPROTEIN CHOLESTEROL IN PEDIATRIC PATIENTS AGED 5 TO 15 YEARS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
EQ 30MG BASE JUXTAPID CHIESI N203858 April 23, 2015 RX CAPSULE ORAL 12472172 July 29, 2041 DOSING REGIMEN TO REDUCE LOW DENSITY LIPOPROTEIN CHOLESTEROL IN PEDIATRIC PATIENTS AGED 5 TO 15 YEARS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
EQ 5MG BASE JUXTAPID CHIESI N203858 Dec. 21, 2012 RX CAPSULE ORAL 12472172 July 29, 2041 DOSING REGIMEN TO REDUCE LOW DENSITY LIPOPROTEIN CHOLESTEROL IN PEDIATRIC PATIENTS AGED 5 TO 15 YEARS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 10MG BASE JUXTAPID CHIESI N203858 Dec. 21, 2012 RX CAPSULE ORAL Feb. 25, 2029 NEW PATIENT POPULATION
EQ 20MG BASE JUXTAPID CHIESI N203858 Dec. 21, 2012 RX CAPSULE ORAL Feb. 25, 2029 NEW PATIENT POPULATION
EQ 2MG BASE JUXTAPID CHIESI N203858 Feb. 25, 2026 RX CAPSULE ORAL Feb. 25, 2029 NEW STRENGTH
EQ 30MG BASE JUXTAPID CHIESI N203858 April 23, 2015 RX CAPSULE ORAL Feb. 25, 2029 NEW PATIENT POPULATION
EQ 40MG BASE JUXTAPID CHIESI N203858 April 23, 2015 DISCN CAPSULE ORAL Feb. 25, 2029 NEW PATIENT POPULATION
EQ 5MG BASE JUXTAPID CHIESI N203858 Dec. 21, 2012 RX CAPSULE ORAL Feb. 25, 2029 NEW PATIENT POPULATION

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Microsomal triglyceride transfer protein large subunit Cytosolic other INHIBITOR IC50 8.10 WOMBAT-PK CHEMBL
Methionine synthase Enzyme IC50 9.30 CHEMBL

External reference:

IDSource
D09637 KEGG_DRUG
4032035 VUID
N0000186142 NUI
4032035 VANDF
C2827241 UMLSCUI
CHEBI:72297 CHEBI
CHEMBL354541 ChEMBL_ID
CHEMBL2105662 ChEMBL_ID
DB08827 DRUGBANK_ID
C473731 MESH_SUPPLEMENTAL_RECORD_UI
7439 IUPHAR_LIGAND_ID
9120 INN_ID
202914-84-9 SECONDARY_CAS_RN
82KUB0583F UNII
9853053 PUBCHEM_CID
1364478 RXNORM
196706 MMSL
29025 MMSL
30485 MMSL
d07939 MMSL
014810 NDDF
014811 NDDF
716228008 SNOMEDCT_US
716229000 SNOMEDCT_US
864003008 SNOMEDCT_US
82KUB0583F INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Juxtapid HUMAN PRESCRIPTION DRUG LABEL 1 10122-402 CAPSULE 2 mg ORAL NDA 34 sections
Juxtapid HUMAN PRESCRIPTION DRUG LABEL 1 10122-405 CAPSULE 5 mg ORAL NDA 34 sections
Juxtapid HUMAN PRESCRIPTION DRUG LABEL 1 10122-410 CAPSULE 10 mg ORAL NDA 34 sections
Juxtapid HUMAN PRESCRIPTION DRUG LABEL 1 10122-420 CAPSULE 20 mg ORAL NDA 34 sections
Juxtapid HUMAN PRESCRIPTION DRUG LABEL 1 10122-430 CAPSULE 30 mg ORAL NDA 34 sections
Juxtapid HUMAN PRESCRIPTION DRUG LABEL 1 76431-105 CAPSULE 5 mg ORAL NDA 33 sections
Juxtapid HUMAN PRESCRIPTION DRUG LABEL 1 76431-110 CAPSULE 10 mg ORAL NDA 33 sections
Juxtapid HUMAN PRESCRIPTION DRUG LABEL 1 76431-120 CAPSULE 20 mg ORAL NDA 33 sections
Juxtapid HUMAN PRESCRIPTION DRUG LABEL 1 76431-130 CAPSULE 30 mg ORAL NDA 33 sections